Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
-
Published:2024-05
Issue:
Volume:71
Page:102582
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Lu HongzhouORCID, Zhang GeorgeORCID, Mao John, Chen Xiaochun, Zhan Yangqing, Lin Ling, Zhang Tianxiang, Tang Yanan, Lin Feng, Zhu Feiyue, Lin Yuanlong, Zeng YimingORCID, Zhang Kaiyu, Yuan Wenfang, Liang Zhenyu, Sun Ruilin, Huo Liya, Hu Peng, Lin Yihua, Zhuang Xibin, Wei Zhaohui, Chen Xia, Yan Wenhao, Yan Xiuping, Mu Lisa, Lin Zhuhua, Tu Xinyu, Tan Hongshan, Huang Fuhu, Hu Zhiqiang, Li Hongming, Li Guoping, Fu Haijun, Yang Zifeng, Chen Xinwen, Wang Fu-Sheng, Zhong Nanshan
Reference29 articles.
1. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5;Hachmann;N Engl J Med,2022 2. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5;Wang;Nature,2022 3. The global landscape of SARS-CoV-2 genomes, variants, and haplotypes in 2019nCoVR;Song;Dev Reprod Biol,2020 4. The 2019 novel coronavirus resource;Zhao;Yi Chuan,2020 5. An online coronavirus analysis platform from the National Genomics Data Center;Gong;Zool Res,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|